Tocilizumab for treatment-resistant depression in Brazil
Treatments studied
Part of Immune system & allergy, Mental health clinical trials.
This study tests whether the drug tocilizumab, which targets inflammation, can improve depression when added to standard care. It is for people with treatment-resistant depression and higher-than-normal inflammation levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and speak/read Portuguese.
- You must have been diagnosed with depression that has not gotten better after at least two different treatments.
- Your depression symptoms must be severe (score of 19 or more on a standard depression rating scale).
- A blood test must show a certain level of inflammation (CRP at least 3 mg/L).
- You must not have bipolar disorder, personality disorder, or substance use disorder in the last 6 months.
- You must not be pregnant, breastfeeding, or have active infections, autoimmune diseases, or serious heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a medication called tocilizumab, which targets inflammation, to see if it can improve symptoms of major depression in people with signs of inflammation. You may be eligible if you have depression with a high monocyte count and significant loss of interest or pleasure.
This trial tests whether a medication that targets inflammation in the body can help relieve depression symptoms. You will have blood tests and an MRI to see how your brain and immune system respond.
This trial tests if cannabidiol (CBD) oil can help people with major depression that has not improved with standard antidepressants. You will take CBD oil or a placebo while continuing your current antidepressant treatment to see if it improves your symptoms.
This study tests whether doctors can choose the best add-on immune-related treatment for people with major depressive disorder by using inflammation blood tests. It’s meant for people whose depression has not improved enough with their current antidepressant.
This trial tests if a medicine called infliximab, given through an IV, can help improve thinking and memory problems in people with moderate to severe depression who also have high inflammation levels. It aims to see if lowering inflammation can ease both mood and cognitive symptoms.
This Phase 2 study looks at whether lowering inflammation can help improve depression symptoms in adults living with HIV. You may be able to join if your HIV is well controlled and you are currently experiencing major depression (or a certain type of bipolar depression).
Hear when a new Treatment-Resistant Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.